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Abstract
Background: Group I L-lactamases are a major cause of
antibiotic resistance to L-lactams such as penicillins and cepha-
losporins. These enzymes are only modestly affected by classic L-
lactam-based inhibitors, such as clavulanic acid. Conversely, small
arylboronic acids inhibit these enzymes at sub-micromolar
concentrations. Structural studies suggest these inhibitors bind
to a well-defined cleft in the group I L-lactamase AmpC; this cleft
binds the ubiquitous R1 side chain of L-lactams. Intriguingly,
much of this cleft is left unoccupied by the small arylboronic acids.
Results : To investigate if larger boronic acids might take
advantage of this cleft, structure-guided in-parallel synthesis was
used to explore new inhibitors of AmpC. Twenty-eight derivatives
of the lead compound, 3-aminophenylboronic acid, led to an
inhibitor with 80-fold better binding (2 ; Ki 83 nM). Molecular
docking suggested orientations for this compound in the R1 cleft.
Based on the docking results, 12 derivatives of 2 were synthesized,
leading to inhibitors with Ki values of 60 nM and with improved
solubility. Several of these inhibitors reversed the resistance of
nosocomial Gram-positive bacteria, though they showed little
activity against Gram-negative bacteria. The X-ray crystal
structure of compound 2 in complex with AmpC was subsequently
determined to 2.1 Aî resolution. The placement of the proximal
two-thirds of the inhibitor in the experimental structure corre-
sponds with the docked structure, but a bond rotation leads to a
distinctly different placement of the distal part of the inhibitor. In
the experimental structure, the inhibitor interacts with conserved
residues in the R1 cleft whose role in recognition has not been
previously explored.
Conclusions: Combining structure-based design with in-parallel
synthesis allowed for the rapid exploration of inhibitor function-
ality in the R1 cleft of AmpC. The resulting inhibitors differ
considerably from L-lactams but nevertheless inhibit the enzyme
well. The crystal structure of 2 (Ki 83 nM) in complex with AmpC
may guide exploration of a highly conserved, largely unexplored
cleft, providing a template for further design against AmpC L-
lactamase. ß 2001 Elsevier Science Ltd. All rights reserved.
Keywords: Antibiotic resistance; Structure-based drug design; Boronic
acids; Transition-state analog; X-ray crystallography
1. Introduction
L-Lactamases catalyze the hydrolysis of L-lactam anti-
biotics, deactivating them. These enzymes are the most
widespread resistance mechanism to drugs of the penicillin
and cephalosporin families, and they threaten public
health [1,2]. To combat these enzymes, medicinal chemists
have introduced L-lactam-based inhibitors, such as clavu-
lanic acid, and ‘L-lactamase-resistant’ L-lactams, such as
aztreonam [3,4]. These anti-resistance L-lactams resemble
the original penicillins and cephalosporins; like the early
penicillins and cephalosporins, many of them are natural
products or simple derivatives of natural products. The
exposure of bacteria to these compounds over evolution-
ary time [5] has allowed bacteria to rapidly acquire resis-
tance to these anti-resistance drugs [6]. To escape from this
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cycle of small modi¢cation and rapid response, it is worth-
while to explore non-L-lactam inhibitors of L-lactamases.
An interesting class of non-L-lactam inhibitors of serine
L-lactamases is the boronic acids [7^12]. These molecules
act competitively, forming reversible adducts with the cat-
alytic serine of the enzymes, adopting a tetrahedral geom-
etry thought to resemble that of the high energy intermedi-
ate (Fig. 1). Although the original leads had only modest
a⁄nity for L-lactamases [7], structure-based design has
recently led to inhibitors with nanomolar a⁄nities
[8,9,11] and anti-microbial activity at low Wg/ml concen-
trations [9,10,12]. The arylboronic acids vary in a⁄nity for
the group I L-lactamase AmpC by four orders of magni-
tude. This is consistent with modeling [9] and crystallo-
graphic studies [10,13] that suggest that a⁄nity for the
enzyme is modulated by the aryl side chains of the inhib-
itors. These interactions take place in the part of the
AmpC cleft thought to be responsible for binding the
R1 side chains of L-lactams [12,14^16] (Fig. 1); we will
refer to this region as the ‘R1 cleft’ of the enzyme (Fig. 2).
Most of the arylboronic acids investigated to date have
been small. Although highly complementary to the enzyme
in the region where they bind, much of the cleft is left
open by these inhibitors [10] (Fig. 2). We wondered
whether larger inhibitors might take advantage of this
open region, and if so, what sort of functionality would
best complement it. The surface of the R1 cleft contains a
number of indentations, and the surface-exposed residues
that line it are highly conserved (Fig. 2), suggesting that
several binding sites may be available. Conversely, the
Fig. 1. (A) A characteristic cephalosporin, cephalothin. The R1 side
chain is labeled. (B) Comparison between the deacylation high energy
intermediate of a cephalosporin in a serine L-lactamase and the transi-
tion-state analog formed by a boronic acid and the same enzyme. The
protonation state of the high-energy intermediate remains an area of re-
search [13,15].
Fig. 2. The molecular surface of the R1 cleft of AmpC L-lactamase from Escherichia coli in complex with benzo(b)thiophene-2-boronic acid [10]. Some
conserved amino acids in this cleft are labeled. Figs. 2, 4, 6, and 7 were generated with MidasPlus [50].
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Table 1
Inhibitors of AmpC synthesized through in-parallel techniques
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function of most of this region is unknown, and there is
little structure^activity information to guide inhibitor de-
sign.
Taking advantage of open clefts is a common problem
in structure-based inhibitor design. The possibility of de-
signing functionality for these sites is one of the advan-
tages of working with atomic resolution structures. Be-
cause they are new sites, designing appropriate ligand
functionality to complement them is challenging. This is
a question not only of predicting favorable interactions,
which is di⁄cult in an aqueous environment [17], but also
of coordinating the design with synthetic feasibility.
To address this question, we adopted a strategy of struc-
ture-guided in-parallel synthesis. This technique can rap-
idly explore derivatives of a lead compound [18,19]. The
ligand functionality explored can be constrained by recep-
tor structural information [20,21], and the structures of
interesting compounds in complex with the enzyme pro-
vide templates for further design. A known inhibitor,
3-aminophenylboronic acid [7,13] (1, Table 1), was used
Table 2
Focused library based on compound 2
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as the lead for the in-parallel syntheses. Although 1 is only
a modest inhibitor of AmpC (Ki 7.3 WM) [7], it is well
suited to derivatization. Modeling studies suggested that
amide and sulfonamide derivatives of 1 would ¢t well into
the R1 cleft of AmpC [9]. Twenty-eight derivatives were
synthesized through polymer-assisted in-parallel chemis-
try, resulting in several inhibitors that bound in the 100
nM range. Flexible ligand docking calculations [22] sug-
gested a conformation of one of these inhibitors, com-
pound 2, in the R1 cleft of AmpC. Based on this predic-
tion, a second, focused library of 12 molecules was
synthesized to improve solubility and inhibition and to
explore the structure^activity relationships (SAR) of the
series (Table 2). Subsequently, the structure of 2 bound
to AmpC was determined by X-ray crystallography to
2.1 Aî resolution. This structure allows us to probe new
recognition elements in the R1 cleft and to determine how
well our docking model predicted the experimental bind-
ing geometry. The structure provides a template for fur-
ther design in this series of L-lactamase inhibitors.
2. Library design
Previous studies of boronic acid adducts of AmpC sug-
gested that amide and sulfonamide derivatives could be
accommodated in the AmpC site [9]. The library was de-
signed to explore a relatively diverse group of such deriv-
atives, taking advantage of the well-understood chemistry
a¡orded by amide and sulfonamide linkers. A substructure
search of the Available Chemicals Database using the ISIS
program (MDL, Inc., San Leandro, CA, USA) suggested
commercially available sulfonyl and acid chlorides that
could extend from the lead compound 1. Sulfonyl chlor-
ides and carbonyl chlorides selected included derivatives of
aryl rings, heterocyclic rings (thiophene, oxazole, diazole),
and condensed rings (naphthalene, quinoline, benzothio-
phene). When possible, substitutions were chosen to mod-
ulate the polarity of the inhibitors. The second, focused
library was designed to explore the SAR of the highest
a⁄nity compound from the ¢rst library, using sequential
liquid phase synthesis.
The ¢rst library of 28 compounds was synthesized using
polymer-assisted liquid phase in-parallel chemistry at
room temperature. 3-Aminophenylboronic acid hemisul-
fate was reacted with 28 di¡erent sulfonyl and carbonyl
chlorides. Poly(4-vinylpyridine) resin (for amide deriva-
tives) or (piperidinomethyl)-polystyrene resin (for sulfon-
amide derivatives) was used to scavenge the hydrochloric
acid formed during the reaction. Aminomethylated poly-
styrene resin was added in a ¢nal step to scavenge the
excess acid chloride [23]. The resins were ¢ltered o¡ and
the ¢ltrate concentrated under vacuum to give the ¢nal
compounds. The second group of 12 compounds was syn-
thesized through multi-step liquid phase chemistry. The
¢nal products were typically isolated through extraction
with organic solvents ; several were further puri¢ed by col-
umn chromatography.
3. Results
Initial modeling suggested that derivatives of 1 would
bind in the R1 cleft, interacting with Leu119, Gln120 and
Scheme 1. In-parallel synthesis of 3-sulfonamide- and 3-amidephenylboronic acids. For amide derivatives, poly(vinylpyridine) resin was used as base.
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Asn152 [9]. Compound 1 was derivatized by carbonyl and
sulfonyl chlorides using polymer-assisted liquid phase in-
parallel chemistry, resulting in 28 amide and sulfonamide
derivatives (Scheme 1). The Ki values of these compounds
ranged from 0.083 to 25 WM (Table 1). The sulfonamides
typically had lower (better) Ki values than the amides.
With few exceptions, the sulfonamides had Ki values less
than 2 WM, whereas the Ki values of the amides ranged
from 3 to 25 WM. Larger molecules with aromatic rings
linked together linearly (e.g., 2 and 4) typically had lower
Ki values than did fused ring systems of about the same
hydrophobicity (e.g., 6 and 9). The most potent compound
of this ¢rst series, 2, inhibited AmpC competitively with a
Ki value of 83 nM by full kinetic analysis (Fig. 3). For
most inhibitors, Ki values were determined using progress
curves, which are accurate for boronic acid inhibitors of
group I L-lactamases [9,24].
Compound 2 was ¢t into the AmpC cleft using £exible
ligand docking [22]. A total of 1584 orientations, each of
which had 500 conformations, were evaluated for steric
and electrostatic complementarity to the enzyme [25]. In
the highest scoring orientation, the boronic acid of 2 hy-
drogen bonds with the main chain nitrogens of Ser64 and
Ala318, the main chain oxygen of Ala318, and the hydrox-
yl of Tyr150 (Fig. 4). These interactions are highly con-
served among L-lactamase^boronic acid complexes [8,10^
13], and the calculation was biased toward them. In the
docked orientation, the ¢rst phenyl ring of 2 forms a di-
pole^quadrupole interaction with the side chain amide of
Asn152 (its NN2 atom comes as close as 2.9 Aî to the
inhibitor ring). The sulfonamide nitrogen of 2 forms a
dipole^quadrupole interaction with the aryl ring of
Tyr221. The bridging thiophene ring is oriented toward
the surface of the R1 cleft. The last, distal ring of the
inhibitor appears to interact with Arg204. From the
docked orientation, it seemed that larger derivatives of 2
might ¢t into the R1 cleft to better interact with residues
such as Arg204 and the ‘omega loop’ [26] of AmpC, in-
cluding residues Val211 and Ser212.
To explore the SAR of sulfonamides resembling 2, 12
further compounds were synthesized using sequential liq-
uid phase chemistry (Scheme 2). These compounds were
designed to be more soluble and to interact with residues
suggested by the docked conformation of 2. Each of these
compounds had a Ki of 1.2 WM or better. The most potent
of them, 33, had a Ki value of 60 nM (Table 2).
Boronic acids are known to inhibit serine proteases, and
it seemed sensible to investigate the selectivity of the new
inhibitors for AmpC. Compound 2 was 200-fold more
active against AmpC than it was against chymotrypsin,
and it was three orders of magnitude more selective for
AmpC than it was against trypsin or elastase (Table 3).
Compounds 2 and 33 were tested in bacterial culture for
their ability to reverse the resistance of L-lactamase-
expressing bacteria to penicillins. At a concentration of
Fig. 3. Lineweaver^Burk plot of the inhibition of AmpC by compound
2. Inhibitor concentrations were: 0 WM (8), 25 WM (F), 50 WM (R),
100 WM (U), and 200 WM (). The Ki value is 83 nM.
Fig. 4. The highest scoring docked orientation of 2 with AmpC. Dashed yellow lines indicate hydrogen bonds. The catalytic serine residue (S64) has
been mutated to a glycine for the docking calculation (see Section 6). Carbon atoms of AmpC are colored orange, carbon atoms of 2 magenta, nitrogen
atoms blue, oxygen atoms red, and sulfur atoms green.
Table 3






aThe substrate to Km ratio for AmpC was 2.5, with a Km value of 40
WM [9]. The substrate to Km ratio for chymotrypsin was 3.4, with a Km
value of 58 WM [47]. The substrate to Km ratio for trypsin was 4, with
a Km value of 50 WM [48]. The substrate to Km ratio for elastase was
0.1, with a Km value of 6.2 mM [49]. See Section 6 for more details.
bNo inhibition was observed at 25 WM. The values given for the IC50
assume that inhibition was no greater than 20% at this concentration.
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23.8 Wg/ml (50 WM), compound 33 potentiated the activity
of ampicillin (200 Wg/ml) against the JM109 strain of Es-
cherichia coli expressing AmpC. However, against clinical
isolates of Gram-negative bacteria, the inhibitors showed
little e¡ect. Both inhibitors were active against Gram-pos-
itive strains thought to express group II L-lactamases. The
inhibitors reduced the minimum inhibitory concentration
(MIC) of amoxicillin by 8^32-fold against these bacteria,
Table 4
MICsa for compounds 2 and 33
Bacterium Amx 2 alone 33 alone Clav alone Amx-2b Amx-33b Amx-Clavc
S. epidermidis 30995 64 256 64 32 8 4 2
S. epidermidis 31091 32 256 64 64 4 4 2
S. aureus 12 64 512 512 4 8 8 0.5
S. aureus 39 64 512 256 8 4 4 0.5
S. aureus 42 256 256 512 s 256 16 16 16
S. aureus 44 128 512 256 16 4 4 1
S. epidermidis 1108 128 256 512 8 4 8 0.5
Micrococcus sp. 3110925 256 128 128 s 256 16 8 32
Bacillus sp. 70002 8 256 256 256 2 4 4
Nocardia sp. s 512 1024 512 s 256 128 256 64
aMIC in Wg/ml; Amx: amoxicillin; Clav: clavulanic acid.
bAmx/inhibitor = 1/3 (w/w).
cAmx/Clav = 2/1 (w/w).
Scheme 2. Sequential synthesis of focused library. (a) NaHCO3, pH 10, 4 N NaOH. (b) H2O/MeOH, Pd/C 10%, H2 2 atm.
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typically to 4^16 Wg/ml (Table 4). Consistent with this
observation, compounds 2, 33, and 41 inhibited PC1 L-
lactamase from Staphylococcus aureus with Ki values in
the 2^6 WM range (Table 5). Compounds 33 and 41
were also found to have micromolar Ki values versus the
group II L-lactamase TEM-1 (Table 5).
To understand in detail how 2 interacted with AmpC,
co-crystals of the enzyme/inhibitor complex were grown.
The crystal di¡racted to 2.7 Aî resolution on a rotating
anode source, and di¡erence electron density maps calcu-
lated from this data set veri¢ed the presence of the inhib-
itor in the active site (Table 6). Re¢nement was begun
using this data set, and the inhibitor was modeled into
the active site. Subsequently, the same crystal showed an
improved di¡raction limit at the Advanced Photon
Source, Argonne National Laboratory, allowing the struc-
ture to be determined and re¢ned to 2.1 Aî resolution
(Table 6). The location and conformation of the inhibitor
was clear in the initial Fo3Fc di¡erence electron density
maps at 2.1 Aî resolution, contoured at 3.0 c, allowing it
to be immediately added to the model. Following re¢ne-
ment, a simulated annealing omit map of the inhibitor was
calculated and showed unambiguous positive di¡erence
density for the inhibitor (Fig. 5). As expected, greater de-
tail was observed in the 2.1 Aî structure; this included
several water molecules interacting with the inhibitor
that were not observed in the 2.7 Aî structure. Other
than the water structure, few changes were observed be-
tween the structure determined to 2.7 Aî and that deter-
mined to 2.1 Aî .
The quality of the ¢nal model for the 2.1 Aî structure
was evaluated with the program Procheck [27]; 90.1% of
Fig. 5. Stereo view of electron density of the re¢ned model of 2 in complex with AmpC. A 2Fo3Fc electron density map is represented by the blue
cage and is contoured at 1.3 c. A simulated-annealing omit map of the inhibitor covalently attached to S64 is represented by the green cage and is con-
toured at 3.0 c. Atoms are colored as in Fig. 4, except all carbon atoms are colored gray. This ¢gure was generated using SETOR [51].
Table 5
Ki values against other L-lactamase enzymes
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the non-glycine and non-proline residues were in the most
favored regions of the Ramachandran plot, and the re-
maining residues were in the additionally allowed region.
The ¢nal R and Rfree values of the re¢ned structure were
20.6% and 24.9%, respectively. This structure has been
deposited in the PDB with accession code 1GA9.
In the crystallographic complex, 2 adopts a jack-knife
structure, folding back upon itself so that the last phenyl
ring of the inhibitor overlies the ¢rst phenyl ring, reducing
the exposure of both to solvent (Fig. 6). The OQ of Ser64
forms a dative covalent bond with the tetrahedral boronic
acid. The O1 hydroxyl of the boronic acid hydrogen bonds
with the main chain nitrogens of Ser64 and Ala318, and
also with the main chain carbonyl oxygen of Ala318 (Ta-
ble 7). The O2 hydroxyl hydrogen bonds with the putative
catalytic base of AmpC, Tyr150 [14,15,28], and with a
well-ordered water molecule (Wat402, Table 7). The ¢rst
phenyl ring (i.e., the ring closest to Ser64) of the inhibitor
appears to form a dipole^quadrupole interaction with NN2
of the key catalytic residue Asn152 (Fig. 6), consistent
with interactions observed crystallographically with a
small arylboronic acid [10]. The sulfonamide nitrogen
(N1) of 2 forms a dipole^quadrupole interaction with
the conserved Tyr221 aryl ring (Fig. 6), similar to inter-
actions observed in the L-lactam loracarbef complex with
AmpC [16]. N1 also interacts with a water molecule
(Wat481). Another ordered water molecule (Wat406) in-
teracts with a sulfonamide oxygen (O4, 2.9 Aî ), Tyr221OH
(2.9 Aî ), Ser212O (2.6 Aî ), and Wat566 (2.9 Aî ). Up to this
point, the crystallographic conformation of 2 closely over-
lies the docked structure (Fig. 7).
The major di¡erence between the docked and the crys-
tallographic structures results from a 165‡ rotation about
the thiophene sulfone bond (i.e., S1 and C10 in Fig. 6),
leading to a di¡erent placement of the ¢nal sulfonyl-phe-
nyl group of the inhibitor. There are smaller conforma-
Table 6
Data collection and re¢nement statistics for the X-ray structures of the complex between compound 2 and AmpC, determined at 2.1 and 2.7 Aî resolu-
tion
2.1 Aî resolution structure 2.7 Aî resolution structure
Cell constants (Aî ; ‡) a = 118.99 b = 78.06 c = 97.79; L= 115.53 a = 119.10 b = 78.04 c = 97.87; L= 115.53
Resolution (Aî ) 2.1 2.7
Unique re£ections 42 312 20 295
Total re£ections 156 406 69 949
Rmerge (%) 7.3 (17.9)a 10.1 (34.5)a
Completeness (%) 89.8 (96.0)a 91.9 (98.4)a
GIf/GcIf 25.2 10.7
Resolution range for re¢nement (Aî ) 20^2.1 (2.18^2.10)a 20^2.7 (2.78^2.70)a
Number of protein residues 710 716
Number of water molecules 318 115
Rmsd bond lengths (Aî ) 0.013
Rmsd bond angles (‡) 1.651
R-factor (%) 20.6
Rfree (%) 24.9b
Average B-factor, protein atoms (Aî 2) 42.2c
Average B-factor, protein atoms (Aî 2, A monomer only) 38.5
Average B-factor, inhibitor atoms (Aî 2) 60.2c
Average B-factor, inhibitor atoms (Aî 2, A monomer only) 50.4
aValues in parentheses are for the highest resolution shell used in re¢nement.
bRfree was calculated with 5% of re£ections set aside randomly.
cValues cited were calculated for both molecules in the asymmetric unit.
Fig. 6. Stereo view of key interactions observed in the complex of 2 with AmpC. Dashed yellow lines indicate hydrogen bonds. Dashed magenta lines
indicate dipole^quadrupole interactions. Cyan spheres represent water molecules. Interaction distances, including distances from 2 to L119 and L293,
are listed in Table 7. Atoms are colored as in Fig. 4, except the carbon atoms of the inhibitor are gray.
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tional changes about the thiophene ring bond with the
second sulfone, and about the sulfone and the ¢nal phenyl
ring. These rotations result in the distal sulfone forming a
hydrogen bond between O6 of the inhibitor and Wat560
and the distal phenyl ring interacting with the conserved
amino acids Leu119 and Leu293 (Table 7, Fig. 6).
4. Discussion
The R1 cleft of AmpC L-lactamase is an intriguing tar-
get for inhibitor design. The region is well de¢ned struc-
turally and is lined by highly conserved amino acids (Fig.
2). Some of these residues, such as Asn152 and Ala318,
are known to bind to the amide functionality at the prox-
imal end of all L-lactam R1 side chains [14^16,29,30] (Fig.
1). Little is known about what role the rest of the R1 cleft
might have in recognizing L-lactams or other molecules.
To investigate the potential of the R1 cleft as a site for
inhibitor discovery, we used guided in-parallel synthesis,
followed by crystallographic structure determination of an
enzyme^inhibitor complex. The resulting derivatives had
Ki values two orders of magnitude better than the initial
lead. Despite this improvement, it is clear that smaller
molecules can be found that bind in the same a⁄nity
range [9]. Also, boronic acids simply bearing the side
chains of L-lactams [31] have been described that bind in
the low nanomolar range to the group II L-lactamase
TEM-1 [11] and in the 20^200 nM range to AmpC [12],
and small aryl boronic acids that bind in the 500 nM
range have been found for the group I L-lactamase from
Pseudomonas [31]. What is unusual about the inhibitors
and structures described here is the rapid elaboration of
novel and disparate chemical functionality through guided
in-parallel synthesis and the recognition of that function-
ality by the R1 cleft of AmpC.
Compound 2 makes several interactions with AmpC
that are common to the small boronic acid inhibitors
[10,13] (our unpublished results), and to a lesser extent a
phosphonate inhibitor, in the ‘oxyanion’ [15] or ‘electro-
philic’ [13] hole of the enzyme. Both the O1 and O2 hy-
droxyls of the inhibitor hydrogen bond with conserved
catalytic residues of AmpC [10] (Fig. 6). The ¢rst phenyl
ring of the inhibitor (that closest to the bound boronic
acid) appears to form dipole^quadrupole interactions
with the key catalytic residue Asn152 [10] (Fig. 6).
New interactions are observed beyond the ¢rst phenyl-
boronic acid. The dipole^quadrupole interaction between
Tyr221 and the sulfonamide nitrogen of 2 mimics a similar
interaction observed between this residue and the amino
group of the substrate loracarbef [16]. Tyr221 is com-
pletely conserved among group I L-lactamases, but its
Table 7
Interactions in the crystallographic complex between 2 and AmpC
aNot present.
Fig. 7. Overlay of the docked and crystallographic conformations of 2 in the AmpC site. Atoms are colored as in Fig. 4, except carbon atoms of the
docked inhibitor are magenta, and carbon atoms of the inhibitor in the crystal structure are gray.
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function is unknown. This residue may commonly interact
with polar or aromatic groups through quadrupolar inter-
actions. The last phenyl ring of the inhibitor jack-knifes
back over the ¢rst phenyl ring, forming van der Waals
interactions with Leu119 and Leu293 (Fig. 6). These res-
idues form a hydrophobic patch on one side of the R1
cleft. Leu119 is completely conserved among group I L-
lactamases, and Leu293 is mostly conserved ^ it is replaced
by Phe or Met in a few enzymes. The role of these residues
in substrate recognition, if any, is unknown. The structure
of 2 suggests that molecules may be designed to take ad-
vantage of the exposed hydrophobic surface area of these
leucines to improve inhibition.
The jack-knifed conformation of 2 helps to explain the
SAR of this family of inhibitors. To adopt this conforma-
tion, tetrahedral linkages are required between the three
aryl rings of the inhibitor. Planar linkages, as in amide
bonds, would lead to an extended conformation of the
inhibitor, resulting in clashes with the binding site. In
the ¢rst series of 28 inhibitors, tetrahedral sulfonamides
are more potent than planar amides, with the nine most
potent compounds all carrying a sulfonamide group (com-
pounds 2^10, Table 1). Comparing compound 21 with 37
and compound 20 with 38, the replacement of an amide by
a sulfonamide improves a⁄nity by 10-fold. Similarly, con-
verting the second sulfonamide of 41 to an amide in 35
results in a seven-fold decrease in binding. On the other
hand, an inversion of the nitrogen and sulfone positions
within this second sulfonamide linkage (compound 33 ver-
sus 41), which maintains the tetrahedral geometry, has
little e¡ect on binding.
The 500-fold range of inhibition values in this series
suggests that speci¢c contacts are being made with the
enzyme and that inhibition cannot be explained solely by
general, non-speci¢c features of these inhibitors. Although
larger derivatives are often more potent than the smaller
ones, neither size nor hydrophobicity is su⁄cient to ex-
plain the binding activity among these molecules. For in-
stance, compound 3 is one of the smaller, but also one of
the better inhibitors (Ki 0.1 WM). Indeed, the larger li-
gands, though the most potent, do not realize as much
potency for their increase in size as one might have ex-
pected. This may owe to the lack of interactions observed
in the middle (thiophene) region of compound 2 in its
complex with AmpC. This middle region may simply serve
as a spacer linking the ¢rst third of the inhibitors, which
make important interactions with the enzyme, to the last
third of the inhibitors, which also appear to make impor-
tant interactions (i.e., with Leu119 and Leu293). More
broadly, small changes in the linker type, position, and
length a¡ect activity signi¢cantly. Two of the most polar
inhibitors, 33 and 41, are also the most potent.
Boronic acids act as transition-state analogs for serine
L-lactamases in general, and also for serine proteases. To
investigate the spectrum of action, we measured the inhi-
bition of three of the most active of the new inhibitors
against the group II L-lactamases PC1 from S. aureus
and TEM-1, and against the group I L-lactamase P99
from Enterobacter cloacae (Table 5). The inhibitors are
100-fold less active against the group II enzymes, but
nevertheless still bind in the low micromolar range, with
the exception of compound 2 against TEM-1. The inhib-
itors bind in the range of 100^250 nM against P99, con-
sistent with its high similarity to AmpC. To investigate
speci¢city of these new inhibitors, compound 2 was tested
against several serine proteases (Table 3), showing better
than 200-fold selectivity versus chymotrypsin and better
than 1000-fold selectivity versus trypsin and elastase, com-
pared to AmpC.
Given the relatively good inhibition of compounds 2,
33, and 41, their poor activity against pathogenic Gram-
negative bacteria expressing group I L-lactamases was dis-
appointing; small arylboronic acids with similar inhibition
values are active against these bacteria [9,10]. This lack of
activity of these larger inhibitors may re£ect di⁄culties
with outer membrane penetration, which is frequently a
problem with antibiotics acting against Gram-negative
bacteria. Consistent with this hypothesis, compounds 2
and 33 were active against several Gram-positive patho-
gens (Table 4), in line with the micromolar Ki values
against the group II L-lactamases expressed by these bac-
teria (Table 5). Although the ability of these inhibitors to
reverse resistance in bacteria such as S. aureus and S.
epidermidis is encouraging, to have broad-spectrum activ-
ity it will be necessary to improve the ability of these
inhibitors to penetrate Gram-negative bacteria.
The structure of 2 in complex with AmpC was deter-
mined to a resolution of 2.7 Aî and subsequently to 2.1 Aî ,
from the same crystal. What additional information did
the higher resolution structure provide us with in our in-
hibitor design e¡orts? The conformation of the inhibitor is
very similar (rmsd between inhibitor atoms is 0.66 Aî ), and
it is observed to make the same interactions with the ami-
no acids of AmpC in both structures. For example, the
interactions made by the boronic acid hydroxyls, the
quadrupole^dipole interactions with Asn152 and Tyr221,
and the interaction of the terminal phenyl ring of 2 with
the hydrophobic patch formed by Leu119 and Leu293 are
maintained. The only signi¢cant di¡erence between the
two structures is in the water structure; several water mol-
ecules that interact with 2 are seen only in the higher res-
olution structure. Several investigators have argued that a
knowledge of the ordered waters can be used in the design
or elaboration of an inhibitor [32^34], and to this extent,
the 2.1 Aî structure is more informative than the 2.7 Aî
structure. Nevertheless, it is clear that most information
in the 2.1 Aî structure is captured in the 2.7 Aî structure, as
far as the inhibitor is concerned. Perhaps the greatest ar-
gument in favor of the higher resolution data is that we
feel more con¢dent about the model that we have ¢t for
them. The ¢nal models do not themselves di¡er signi¢-
cantly.
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We used a docked structure of 2 in AmpC to design the
second library of inhibitors, since a crystallographic com-
plex was not available at that time. Subsequently, the
structure of the complex with compound 2 was determined
by X-ray crystallography; it is appropriate to ask how well
this predicted structure corresponded to the experimen-
tally determined structure, and how useful the model
was in predicting new compounds. The docked and crys-
tallographic conformations of 2 resemble each other
closely for most of the molecule (Fig. 7). A ring £ip in
the thiophene leads to a di¡erent placement of the last
phenyl ring, with the docked structure extending into the
distal region of the R1 cleft and the crystallographic struc-
ture folding back upon itself in the proximal region of the
cleft. As in previous studies, the docking program was able
to predict the placement of the inhibitor to ‘low resolu-
tion’ [35^37]. Most of the inhibitor is correctly placed, but
several key interactions are missed, probably owing to
under-sampling conformations in the docking calculations.
How useful was the docked prediction in designing the
second library of inhibitors? Both the docked structure
and the SAR in this series suggested that tetrahedral sul-
fonamides would do better than planar amides, which led
us to focus on the former in the second library. The
docked structure properly suggested that the central thio-
phene of 2 functioned as a linker, making few interactions
on its own, and could be replaced with more synthetically
tractable groups, such as the phenyl ring used in most
compounds in the second library. On the other hand,
our failure to predict the placement of the last phenyl
ring led to derivatives that were designed to complement
the polar, distal part of the R1 cleft, as opposed to the
hydrophobic patch made up of Leu119 and Leu293. Had
the crystallographic complex of 2 with AmpC been avail-
able, we would have explored di¡erent derivatives, espe-
cially in the distal portion of the inhibitors, in the second
library.
This said, the combination of structure-based design
with in-parallel synthesis allowed for the rapid exploration
of novel inhibitor functionality in the R1 cleft of AmpC.
The crystallographic complex of the 83 nM inhibitor 2 is a
guide to recognition in this cleft and a template for further
design against AmpC L-lactamase. The unusual dipole^
quadrupole interaction with the completely conserved
Asn152 seems to be a conserved feature in arylboronic
acids. In some ways this is surprising, since the same as-
paragine donates a hydrogen bond to the R1 amide car-
bonyl of L-lactams. Aryl rings are not typically considered
good replacements for carbonyl oxygens, but in arylbo-
ronic acids this appears to be a critical contribution to
the a⁄nity [9,10]. The dipole^quadrupole interaction be-
tween the sulfonamide nitrogen and Tyr221 may be char-
acteristic of this residue [10,16]. Similarly, the role of the
exposed, conserved Leu119 and Leu293 in substrate rec-
ognition is not understood at this time. The interaction of
these residues with the last phenyl ring of 2 suggests that,
irrespective of what these residues may contribute to L-
lactam recognition, they can be used in the design of
non-L-lactam inhibitors of AmpC.
5. Signi¢cance
Group I L-lactamases are a major cause of antibiotic
resistance to L-lactams such as penicillins and cephalo-
sporins. Known L-lactam-based inhibitors of L-lactamases
have little e¡ect on these enzymes, which are increasingly
prevalent in hospital pathogens. To investigate potential
complementarity of inhibitors for an open binding cleft
observed in the structure of AmpC, a combination of
structure-based design and in-parallel synthesis was
adopted. This led to inhibitors with a 100-fold better af-
¢nity than the lead compound, exploring a wide range of
derivatives. Several of these inhibitors reversed the resis-
tance of Gram-positive bacteria, although they were much
less e¡ective against L-lactam-resistant Gram-negative
bacteria. The crystal structure of an 83 nM inhibitor, in
complex with the group I L-lactamase AmpC, suggests
recognition roles for residues in the enzyme that are highly
conserved but for which no function had previously been
detected. This structure may serve as a template for future
design in this series.
6. Materials and methods
6.1. Synthetic chemistry
3-Aminophenylboronic acid hemisulfate was purchased from
Aldrich. Sulfonyl and carbonyl chlorides were purchased from
Aldrich, Maybridge International, TCI-US, Lancaster, Fluka,
and Asinex. (Piperidinomethyl)-polystyrene (2.6 mmol base/g res-
in; crosslinked with 2% divinyl-benzene (DVB); 200^400 mesh)
and poly(4-vinylpyridine) (8.8 mmol base/g resin; crosslinked
with 2% DVB; 60 mesh) resins were purchased from Fluka. Ami-
nomethylated polystyrene (1.33 mmol base/g resin) was pur-
chased from Novabiochem.
Liquid phase in-parallel synthesis was carried out on a 10-po-
sition platform shaker. The catalytic hydrogenation was accom-
plished using a stirred Reactor ‘Parr’, Mod.4561 3000 psi Mag-
netic Drive T316 Stainless Steel 230 V 50/60 Hz Air Motor.
The purity of all synthesized compounds was determined by
thin layer chromatography (TLC) and by elementary analysis.
For TLC, pre-coated silica gel 60 F254 plates (Merck) were
used. The plates were viewed using a UV/visible lamp at 254
nm and 366 nm. Silica gel (60M; 230^400 mesh, ASTM) was
used for column chromatography. Elementary analyses were car-
ried out in the microanalysis laboratory of the Dipartimento di
Scienze Farmaceutiche, Modena University. Analyses were with-
in þ 0.4% of the theoretical values. All compounds were analyzed
by one-dimensional 1H NMR on Bruker AC200 and Bruker
MX400 WB spectrometers (Centro Interdipartimentale Grandi
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Strumenti, Modena University). Several compounds were also
characterized through two-dimensional 1H NMR. Unless other-
wise stated, spectra were recorded in DMSO-d6. Chemicals shifts
are reported in ppm from tetramethylsilane as internal standard.
6.2. Polymer-assisted liquid phase in-parallel chemistry
6.2.1. Synthesis of 3-acylamino- and 3-sulfonylaminophenylboronic
acid derivatives using aminomethylated polystyrene resin as
a scavenger (Compounds 2^29)
The syntheses were carried out in liquid phase in parallel
(Scheme 1). For the synthesis of a single compound, 0.030 g
(0.161 mmol) of 3-aminophenylboronic acid hemisulfate was sus-
pended in anhydrous chloroform (CHCl3 ; 6 ml), and the mixture
was stirred at room temperature. Poly(4-vinylpyridine) resin (3 eq.,
0.483 mmol; 8.8 mmol/g; 0.054 g) or (piperidinomethyl)-poly-
styrene resin (3 eq., 0.483 mmol; 2.6 mmol/g; 0.186 g) for amide
or sulfonamide derivatives, respectively, was then added to the
stirring mixture as scavenger. Di¡erent acid chlorides and sulfo-
nyl chlorides (R-COCl or R-SO2Cl, 1.5 eq., 0.241 mmol) were
added to each batch, and the reactions were stirred until disap-
pearance or great reduction of starting materials (reaction time
12^24 h). In the latter case, it was necessary to isolate the ¢nal
product from starting materials. This procedure is described be-
low for compounds 2^9, 12, 13, 21^24, 26, 27. Aminomethylated
polystyrene resin (3 eq., 0.483 mmol; 1.33 mmol/g; 0.363 g) was
added to the stirring mixture to scavenge the excess carbonyl or
sulfonyl chloride and stirring was maintained for 4^5 h [23]. The
resins were ¢ltered o¡ and the ¢ltrate concentrated under vacuum
to give the ¢nal 3-acylamino- or 3-sulfonylaminophenylboronic
acid derivative.
TLC analysis of the reaction mixtures of compounds 2 and 4
showed presence of starting materials. The expected products
were then puri¢ed through column chromatography (silica gel
60M; 230^400 mesh ASTM eluent system CH2Cl2/CH3OH; 9:1).
TLC analysis of the reaction mixtures of compounds 3, 5^7, 9,
12, 13, 21^23, and 26 showed the presence of unreacted 3-amino-
phenylboronic acid. The desired products were separated as fol-
lows. The reaction mixture was treated with 4 N hydrochloric
acid and then extracted three times with dichloromethane
(CH2Cl2). The combined organic layers, containing the desired
product, were dried over sodium sulfate (Na2SO4), ¢ltered, and
concentrated under vacuum. The collected product was then tri-
turated and washed with ethyl ether.
TLC analysis of the reaction mixture of compounds 8, 24, and
27 showed the presence of the starting chloride, which was not
completely scavenged by the aminomethylated polystyrene resin,
and unreacted 3-aminophenylboronic acid. The reaction mixture
was therefore treated with 4 N NaOH and then extracted with
dichloromethane (CH2Cl2). The combined organic layers were
dried over Na2SO4, ¢ltered, and concentrated under vacuum to
reduce the volume. The same organic phase was then treated as
described above for compounds 3, 5^7, 9, 12, 13, 21^23, and 26.
Compounds 2, 3, and 4 were also synthesized through traditional
liquid phase synthesis in larger amounts (see below). Purity and
yields of compounds synthesized in parallel, as well as elementary
analysis data, are available in Tables 8 and 9.
6.3. Liquid phase synthesis
6.3.1. 3-(4-Benzenesulfonyl-thiophene-2-sulfonylamino)-
phenylboronic acid (2)
0.3 g (1.61 mmol) of 3-aminophenylboronic acid hemisulfate
(1) was dissolved in sodium bicarbonate (0.5 M NaHCO3, 30 ml)
followed by pH adjustment to 10 using sodium hydroxide (4 N
NaOH). The solution, kept under stirring at room temperature,
was then added to the 4-(benzenesulfonyl)-thiophene-2-sulfonyl
chloride (1.5 eq.; 2.415 mmol, 0.779 g) already dissolved in ace-
tone (10 ml). After stirring overnight, the solution was acidi¢ed
with hydrochloric acid (4 N HCl) and extracted with dichloro-
methane (CH2Cl2) three times. The combined organic layers
were dried over sodium sulfate (Na2SO4) and the solvent re-
moved under vacuum. The collected crude product was then
crystallized from acetone/petroleum ether 60:80. Yield: 0.163 g,
24%.
1H NMR (DMSO) N 7.17 (1H, dd, H-3), 7.29 (1H, t, H-2), 7.65
(1H, d, H-1), 7.73 (2H, t, H-8, H-10), 7.61 (1H, s, H-4), 8.75 (1H,
s, H-6), 7.78 (1H, s, H-5), 7.83 (1H, t, H-9), 8.17 (B(OH)2, s), 9.00
(2H, d, H-7, H-11), 10.54 (NHSO2, s). Cosy correlation: H1^H2,
H2^H3, H3^H4, H7^H8, H8^H9.
Table 8
Purities and yields for compounds synthesized in parallel
Compound Purity (%) Chloride (eq.)a Yield (%)
2 98 1.5 24
3 60 3 32
4 80 1.5 1
5 90 3 13
6 90 3 6
7 60 1.5 5
8 80 3 8
9 70 3 21
10 80 3 14
11 60 1.5 13
12 70 3 8
13 70 1.5 6
14 80 1.5 47
15 70 1.5 9
16 70 4.5 8
17 70 3 18
18 80 3 21
19 70 1.5 70
20 80 1.5 38
21 70 1.5 7
22 70 1.5 13
23 90 1.5 28
24 70 3 9
25 90 3 38
26 80 1.5 18
27 70 3 4
28 70 1.5 42
29 70 1.5 10
aMolar equivalent chloride used for the synthesis.
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6.3.2. 3-(3,5-Dimethyl-isoxazole-4-sulfonylamino)-phenylboronic
acid (3)
0.2 g (1.075 mmol) of 3-aminophenylboronic acid hemisulfate
(1) was dissolved in sodium bicarbonate (0.5 M NaHCO3, 20 ml)
followed by pH adjustment to 10 using sodium hydroxide (4 N
NaOH). The solution, kept under stirring at 30‡C, was then
added to the 3,5-dimethyl-isoxazole-4-sulfonyl chloride (1.5 eq.;
1.61 mmol, 0.315 g) already dissolved in acetone (10 ml)
[52]. After stirring 4^5 h, the insoluble portion was ¢ltered o¡,
and the clear solution was acidi¢ed with hydrochloric acid (4 N
HCl) and extracted with ethylacetate three times (15 ml each).
The combined organic layers were dried over sodium sulfate
(Na2SO4) and the solvent removed under vacuum. The col-
lected product was then triturated with ethyl ether. Yield:
0.124 g, 39%.
1H NMR (DMSO) N 2.18 (CH3, s), 2.29 (CH3, s), 7.20 (1H, d,
H-3), 7.37 (1H, t, H-2), 7.62 (1H, d, H-1), 7.69 (1H, s, H-4), 8.11
(B(OH)2, s), 10.35 (NHSO2, s).
6.3.3. 3-(5-Benzenesulfonyl-thiophene-2-sulfonylamino)-
phenylboronic acid (4)
Compound 4 was prepared according to the method described
for 3 starting from 0.2 g (1.075 mmol) of 1 and 5-benzenesulfo-
nyl-thiophene-2-sulfonyl chloride (1.5 eq.; 1.61 mmol, 0.521 g).
Yield: 0.140 g, 31%.
1H NMR (DMSO) N 7.23 (1H, dd, H-3), 7.35 (1H, t, H-2), 7.59
(2H, d, H-5, H-6), 7.66 (1H, d/o, H-1), 7.66 (1H, d/o, H-4), 7.76
(1H, t/o, H-8), 7.79 (1H, t, H-9), 7.90 (2H, d, H-5, H-6), 8.29
(B(OH)2, s), 8.60 (1H, d, H-7), 10.69 (NHSO2, s). Cosy correla-
tion: H1^H2, H2^H3, H3^H4, H5^H6, H7^H8, H8^H9.
6.3.4. 3-(5-Chloro-4-nitro-thiophene-2-sulfonylamino)-
phenylboronic acid (30)
Compound 30 was prepared according to the method described
for 3 starting from 1 (0.2 g, 1.075 mmol) and 5-chloro-4-nitro-
thiophene-2-sulfonyl chloride (0.423 g, 1.5 eq.). The ¢nal crude
product, 0.144 g, was puri¢ed by column chromatography using
CH2Cl2/CH3OH 9:1 as eluent. Yield: 0.08 g, 21%.
1H NMR (DMSO) N 7.32 (1H, dd, H-3), 7.41 (1H, t, H-2), 7.67
(1H, d/o, H-1), 7.67 (1H, s/o, H-4), 7.72 (1H, s, H-5), 7.99
(B(OH)2, s), 10.8 (NHSO2, s).
6.3.5. 3-{5-[(4-Chloro-benzoylamino)-methyl]-thiophene-2-
sulfonylamino}-phenylboronic acid (31)
Compound 31 was prepared according to the method described
for 3 starting from 1 (0.1 g, 0.54 mmol) and 5-(4-chloro-benzoyl-
amino)-methyl]-thiophene-2-sulfonyl chloride (0.282 g, 1.5 eq.).
The crude product, 0.240 g, was puri¢ed by column chromatog-
raphy with CH2Cl2/CH3OH 9:1 as eluent. Yield: 0.07 g, 27%.
1H NMR (DMSO) N 4.5 7 (CH3, s), 7.09 (1H, d, H-6), 7.29
Table 9
Elementary analysis data for selected compounds
Compound Formula MW C% H% N%
2a C16H14NO6S3B 423.30 45.40 3.34 3.31 % calc
45.44 3.36 3.30 % found
3a C11H13N2O5SB 296.12 44.62 4.43 9.46 % calc
44.74 4.44 9.43 % found
4a C16H14NO6S3B 423.30 45.40 3.34 3.31 % calc
45.58 3.23 3.32 % found
30 C10H8N2O6S2BCl 362.58 33.12 2.23 7.73 % calc
33.21 2.21 7.75 % found
31 C18H16N2O5S2ClB 450.74 47.96 3.59 6.22 % calc
47.80 3.60 6.24 % found
32 C18H17N2O5S2B 416.29 51.93 4.12 6.73 % calc
52.05 4.15 6.70 % found
33 C18H18N2O8S2B2 476.11 45.40 3.82 5.89 % calc
45.54 3.84 5.92 % found
34 C18H12N2O7SBCl3 517.54 41.77 2.34 5.41 % calc
41.63 2.35 5.38 % found
35 C20H17N2O7SB 440.25 54.56 3.90 6.36 % calc
54.38 3.88 6.37 % found
36 C13H12NO6SB 321.13 48.62 3.77 4.63 % calc
48.80 3.75 4.62 % found
37 C12H11N2O6SB 322.12 44.74 3.45 8.70 % calc
44.58 3.44 8.68 % found
38 C12H11N2O6SB 322.12 44.74 3.45 8.70 % calc
44.81 3.47 8.72 % found
39 C12H13N2O4SB 292.13 49.33 4.49 9.59 % calc
49.49 4.52 9.61 % found
41 C19H17N2O8S2B 476.30 47.91 3.60 5.88 % calc
48.02 3.60 5.91 % found
42 C19H17N2O8S2B 476.30 47.91 3.60 5.88 % calc
47.73 3.57 5.85 % found
aCompound was resynthesized and puri¢ed as described in Section 6.
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(1H, dd, H-3), 7.32 (1H, t, H-2), 7.45 (1H, d, H-5), 7.59 (1H, d/o,
H-1), 7.59 (1H, s/o, H-4), 7.65 (2H, d, H-8, H-9), 7.95 (2H, d,
H-7, H-10), 9.36 (CONH, t), 10.33 (NHSO2, s).
6.3.6. 3-{5-[(Benzoylamino)-methyl]-thiophene-2-sulfonylamino}-
phenylboronic acid (32)
Compound 32 was prepared according to the method described
for 3 starting from 1 (0.1 g, 0.54 mmol) and 5-(benzoylamino)-
methyl-thiophene-2-sulfonyl chloride (0.255 g, 1.5 eq.). Yield:
0.180 g, 80%.
1H NMR (DMSO) N 4.68 (CH2, s), 5.57 (1H, s/o, H-4), 7.086
(1H, d, H-6), 7.28 (1H, d/o, H-3), 7.32 (1H, t, H-2), 7.45 (1H, d,
H-5), 7.57 (1H, d/o, H-1), 7.65 (3H, m/o, H-8, H-9, H-10), 7.94
(2H, dd, H-7, H-11), 9.29 (NHCO, t), 10.32 (NHSO2, s).
6.3.7. 3,3P(1Q,3Q-Benzenedisulfonamide) phenylboronic acid (33)
Compound 33 was prepared according to the method described
for 3 starting from 1 (0.141 g, 0.762 mmol) and 1,3-benzenedi-
sulfonyl chloride (0.363 mmol 0.1 g). The ¢nal product was pu-
ri¢ed by column chromatography using CH2Cl2/CH3OH 95:5 as
eluent. Yield: 0.083 g, 64%.
1H NMR (DMSO) N 7.05 (2H, dd, H-3, H-3P), 7.24 (2H, t, H-2,
H-2P), 7.57 (2H, d/o, H-1, H-1P), 7.57 (2H, s/o, H-4, H-4P), 7.76
(1H, t, H-6), 7.97 (1H, dd, H-5), 7.97 (1H, dd, H-7), 8.185 (1H, d,
H-8), 8.86 (B(OH)2, s), 10.40 (NHSO2, s), 10.72 (SO2NH, s).
6.3.8. 3-[3,5-Dichloro-4-(2-chloro-4-nitro-phenoxy)-benzene-
sulfonylamino]-phenylboronic acid (34)
Compound 34 was prepared according to the method described
for 3 starting from 1 (0.08 g, 0.43 mmol) and 3,5-dichloro-4-(2-
chloro-4-nitro-phenoxy)-benzenesulfonyl chloride (0.359 g, 2 eq.).
The ¢nal crude product, 0.2 g, was puri¢ed by column chroma-
tography using CH2Cl2/CH3OH 9:1 as eluent. Yield: 0.090 g,
40%.
1H NMR (DMSO) N 6.78 (1H, d, H-7), 7.19 (1H, dd, H-8),
7.29 (1H, dd, H-3), 7.41 (1H, t, H-2), 7.55 (1H, d, H-9), 7.55




Compound 35 was prepared according to the method described
for 3 starting from 1 (0.15 g, 0.806 mmol) and 3-(4-carboxy-ben-
zoylamino)-benzene sulfonyl chloride (1.21 g, 1.5 eq.). The crude
product was puri¢ed by column chromatography using CH2Cl2/
CH3OH 9:1 as eluent. Yield: 0.06 g, 18%.
1H NMR (DMSO) N 7.26 (1H, d/o, H-3), 7.305 (1H, t, H-2), 7.57
(1H, d, H-1), 7.57 (1H, s/o, H-4), 7.81 (1H, t, H-6), 7.95 (2H, d,
H-10, H-11), 8.01 (1H, d/o, H-7), 8.05 (2H, d, H-9, H-12), 8.28 (1H,
d, H-5), 8.43 (1H, s, H-8), 10.35 (NHCO, s), 10.81 (NHSO2, s).
6.3.10. 3-(4-Carboxy-benzenesulfonylamino)-phenylboronic acid
(36)
Compound 36 was prepared according to the method described
for 3 starting from 1 (0.1 g, 0.54 mmol) and 4-(chlorosulfonyl)
benzoic acid (0.355 g, 3 eq.). Yield: 0.046 g, 27%.
1H NMR (DMSO) N 7.58 (1H, d/o, H-1), 7.22 (1H, dd, H-3),
7.30 (1H, t, H-2), 7.58 (1H, s/o, H-4), 7.93 (2H, d, H-6, H-7), 8.02
(B(OH)2, s/o), 8.15 (2H, d, H-5, H-8), 10.45 (NHSO2, s).
6.3.11. 3-(3-Nitro-benzenesulfonylamino)-phenylboronic acid (37)
Compound 37 was prepared according to the method described
for 3 starting from 1 (0.2 g, 1.075 mmol) and 3-nitro-benzene
sulfonyl chloride (0.357 g, 1.5 eq.). Yield: 0.180 g, 52%.
1H NMR (DMSO) N 7.23 (1H, dd, H-3), 7.32 (1H, t, H-2), 7.52
(1H, d, H-1), 7.59 (1H, s, H-4), 8.09 (B(OH)2, s), 8.20 (1H, d,
H-7), 8.53 (1H, d, H-5), 8.58 (1H, s, H-8), 9.94 (1H, t, H-6), 10.48
(NHSO2, s).
6.3.12. 3-(4-Nitro-benzenesulfonylamino)-phenylboronic acid (38)
Compound 38 was prepared according to the method described
for 3 starting from 1 (0.4 g, 2.15 mmol) and 4-nitro-benzene
sulfonyl chloride (0.477 g, 1 eq.). Yield: 0.559 g, 81%.
1H NMR (DMSO) N 7.21 (1H, dd, H-3), 7.32 (1H, t, H-2), 7.55
(1H, d, H-1), 7.55 (1H, s/o, H-4), 8.04 (2H, d, H-6, H-7), 8.42
(2H, d, H-5, H-8), 10.53 (NHSO2, s).
6.3.13. 3-(3-Amino-benzenesulfonylamino)-phenylboronic acid
(39)
The starting nitro derivative (37) (0.1 g, 0.311 mmol) was dis-
solved in a mixture of water (30 ml) and methanol (10 ml). The
catalyst Pd/C (13%, 0.013 g) was added to the solution, trans-
ferred to a reactor, and stirred under 2 atm of H2 for 1 h [53]. At
the end of the reaction, the catalyst was ¢ltered o¡ and the so-
lution concentrated under vacuum, giving the pure reduced ami-
no derivatives. Yield: 0.070 g, 77%.
6.3.14. 3-(4-Amino-benzenesulfonylamino)-phenylboronic
acid (40)
The starting nitro derivative (38) (0.2 g, 0.311 mmol) was dis-
solved in a mixture of water (60 ml) and methanol (20 ml). The
catalyst Pd/C (10%, 0.020 g) was then added to the solution,
transferred to a reactor, and stirred under 2 atm of H2 for 1 h
[53]. The catalyst was then ¢ltered o¡ and the solution concen-
trated under vacuum, giving the reduced amino derivatives.
Yield: 0.160 g, 88%.
1H NMR (DMSO) N 6.61 (2H, d, H-6, H-7), 7.21 (1H, dd/o,
H-3), 7.27 (1H, t/o, H-2), 7.3 (NH2, o), 7.43 (2H, d, H-5, H-8),




Compound 41 was prepared according to the method described
for 3 starting from 39 (0.04 g, 0.137 mmol) and 4-carboxy-ben-
zenesulfonyl chloride (0.045 g, 1.5 eq.). The ¢nal product, 0.015
g, was puri¢ed through column chromatography using CH2Cl2/
CH3OH 9:1 as eluent. Yield: 0.008 g, 12%.
1H NMR (DMSO) N 7.07 (1H, d, H-3), 7.20 (1H, t, H-2), 7.30
(1H, t/m, H-6), 7.46 (2H, d, H-5, H-7), 7.56 (1H, d, H-1), 7.59
(1H, s, H-4), 7.85 (1H, s, H-8), 7.87 (2H, d, H-9, H-12), 8.15 (2H,
d, H-10, H-11), 10.05 (NHSO2, s), 10.28 (NHSO2, s), 10.98
CHBIOL 99 5-6-01 Cyaan Magenta Geel Zwart
Research Paper Inhibitors of AmpC L-lactamase D. Tondi et al. 607
(COOH, s). Cosy correlation: H1^H2, H2^H3, H3^H4, H5^H6,
H8^H5, H8^H6, H8^H7, H9^H10.
6.3.16. 3-[4-(4-Carboxy-benzenesulfonylamino)-benzenesulfonyl-
amino]-phenylboronic acid (42)
Compound 42 was prepared according to the method described
for 3 starting from 40 (0.1 g, 0.343 mmol) and 4-carboxy-ben-
zenesulfonyl chloride (0.113 g, 1.5 eq.). The ¢nal product, 0.143 g,
was puri¢ed by column chromatography using CH2Cl2/CH3OH
9:1 as eluent. Yield: 0.019 g, 12%.
1H NMR (CD3COCD3) N 7.32 (1H, d/o, H-3), 7.35 (1H, t,
H-2), 7.46 (2H, d, H-6, H-7), 7.78 (1H, d/o, H-1), 7.78 (1H,
s/o, H-4), 7.82 (2H, d/o, H-5, H-8), 8.073 (2H, d, H-10, H-11),
8.28 (2H, d, H-9, H-12), 8.92 (SO2NH, s), 9.79 (NHSO2, s).
6.4. Enzymology
Stock solutions of the inhibitors were made up in dimethylsulf-
oxide (DMSO) at 10 mM, and subsequent 10-fold or 100-fold
stock dilutions were made into 50 mM potassium phosphate bu¡-
er, pH 7.0. Assay conditions for AmpC L-lactamase and P99
L-lactamase from E. cloacae were the same, as described [9]. The
P99 enzyme was a gift from Sergei Vakulenko and was used
without further puri¢cation. All reactions were initiated by en-
zyme in an HP8453 UV/visible spectrophotometer with multi-cell
transport running HP ChemStation software (version 2.5). The
hydrolysis of the substrates cephalothin (for AmpC) or furyl-
acrylpenicillanic acid (FAP) (for PC1 L-lactamase) was monitored
at 265 and 340 nm, respectively. For PC1 L-lactamase from
S. aureus (a gift from Robert Bonomo), 50 mM potassium phos-
phate, pH 7.0 was used as a bu¡er. The concentration of enzyme
in the assays was 3U1034 mg/ml, based on dilution from the
stock solution provided. Reactions were monitored in methacry-
late cuvettes. The Km of FAP for this enzyme was determined to
be 8 WM, and this value was used in the determination of Ki
values using the progress curve method [7,9]. For TEM-1, 50
mM potassium phosphate, pH 7.0 was used as bu¡er. The con-
centration of enzyme in the assays was 7.7U1032 WM. Reactions
were monitored in methacrylate cuvettes. The Km of FAP for
TEM-1 was determined to be 17 WM, and this value was used
in the determination of Ki values using the progress curve method
[7,9]. The Km values of cephalothin for AmpC and P99 were 40
WM and 11 WM, respectively, and these values were used to de-
termine Ki values using progress curves [7,9]. Several compounds
were tested for e¡ects of pre-incubation, but none was noted,
consistent with earlier studies [9,24].
For the Lineweaver^Burk analyses of 2, initial reaction rates
were calculated from ¢ts to the time course of each reaction. At
least three rate values for each substrate^inhibitor combination
were determined. These values were averaged together and plot-
ted (Fig. 3).
Inhibition assays against K-chymotrypsin, trypsin, and elastase
were performed in conditions as described [12]. The substrates
were: for chymotrypsin, N-benzoyl-L-tyrosine-ethyl-ester, 200
WM; for trypsin, N-benzoyl-L-arginine-ethyl-ester, 200 WM; for
elastase MeOSuc-Ala-Ala-Pro-Val-pNA, 640 WM. All reactions
were initiated with enzyme.
6.5. Molecular docking
Flexible ligand docking [22] was used to ¢t 2 into AmpC, using
structure 1C3B [10] from the PDB. An ensemble of 500 low en-
ergy conformations of 2 was calculated using Sybyl (Tripos, St.
Louis, MO, USA). The boron atom was replaced by an sp3 car-
bon, since the boron parameters were not present in the Sybyl
database; the lengths of the B^O and B^C bonds were manually
corrected based on the X-ray crystal structure of benzo(b)thio-
phene-2-boronic acid bound to AmpC [10]. A formal charge of
31 was assigned to the boronic acid group, consistent with its
charge state in the adduct [13,38]; this charge was localized to the
boronic oxygen atoms. Gasteiger^Marsili [39] charges were calcu-
lated for the other inhibitor atoms. All rotatable bonds were
sampled in 120‡ increments, with the exception of the carbon^
boron bond, which was not rotated, and the bond between the
3-amino and the phenyl ring, which was rotated in 60‡ increments
[22].
In the docking calculation, pseudo-atom ‘spheres’ were created
by merging atom positions of four inhibitors that had been pre-
viously crystallized with AmpC or the group I L-lactamase from
E. cloacae. The inhibitors were 3-aminophenylboronic acid [13],
3-nitrophenylboronic acid (Powers and Shoichet, unpublished),
benzo(b)thiophene-2-boronic acid [10], and m-carboxyphenyl
((N-((p-iodophenyl)acetyl)amino)methyl) phosphonate [15]. A to-
tal of 31 atoms from these structures were used as ‘spheres’.
Critical spheres corresponding to the positions of the boronic
hydroxyls from 3-nitrophenylboronic acid and benzo(b)thio-
phene-2-boronic acid were used to restrict the sampling of the
site. Chemical labeling of these spheres [40] biased the docking
to match the boronic acid moiety of 2 to these spheres. A dis-
tance tolerance of 1.2 Aî was used for matching ligand atoms onto
sphere positions; a maximum of ¢ve and a minimum of four
atom^sphere overlaps were imposed to specify an orientation.
To allow for a close, covalent approach between the OQ of
Ser64 and the boron atom of the inhibitor, the CL and OQ
atoms of the Ser were deleted from the structure of the enzyme.
Steric ¢t was evaluated using a grid calculated by the program
DISTMAP [40]; allowed polar and non-polar contacts were set
to a minimum of 2.3 and 2.6 Aî , respectively. Van der Waals
interaction energies were calculated using grids from the pro-
gram CHEMGRID [25] based on the AMBER potential [41].
Electrostatic interaction energies were calculated using grids
from the program DelPhi [42]. Rigid body minimization was
not used.
6.6. Crystal growth and structure determination
Co-crystals of 2 were grown by vapor di¡usion in hanging
drops equilibrated over 1.7 M potassium phosphate bu¡er (pH
7.0) using microseeding techniques. The initial concentration of
protein in the drop was 95 WM, and the concentration of the
inhibitor was 600 WM. The inhibitor was added to the crystalli-
zation drop in a 2% DMSO, 1.7 M potassium phosphate bu¡er
(pH 7.0) solution. Crystals appeared after several months with
equilibration at 23‡C.
The 2.7 Aî data set was collected on an R-Axis IIC image plate
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system at 3170‡C. Data for the 2.1 Aî structure were collected on
the DND-CAT beam line (5IDB) of the Advanced Photon
Source at Argonne National Lab at 100 K using a 162 mm
Mar CCD detector. Prior to data collection, crystals were im-
mersed in a cryoprotectant solution of 20% sucrose, 1.7 M po-
tassium phosphate, pH 7.0, for about 20 s, then £ash cooled in
liquid nitrogen. Both the 2.1 Aî and the 2.7 Aî data sets were
collected from the same crystal.
Re£ections were indexed, integrated, and scaled using the HKL
program suite [43] (Table 6). The space group was C2, with two
AmpC molecules in the asymmetric unit. Each AmpC molecule
contains 358 residues, but electron density for residues B43^45
and B202^204 of molecule 2 was not observed, so they were
deleted from the model. The structure was determined by molec-
ular replacement using an AmpC/boronic acid complexed struc-
ture [10], with inhibitor and water molecules removed, as the
initial phasing model. The model was re¢ned using the maximum
likelihood target in CNS and included a bulk solvent correction
and a sigma cuto¡ of 2.0 [44]. Sigma A-weighted electron density
maps were calculated using CNS, and manual rebuilding was
done in the program O [45]. The inhibitor was built into the
observed di¡erence density in each active site of the asymmetric
unit, and the structure of the complex was further re¢ned using
CNS (Table 6). All atoms were re¢ned with an occupancy of 1.0,
with the exception of residues A172 and B293. These residues
were observed in two conformations and were modeled as such,
with all atoms of each residue having an occupancy of 0.5 for
each of the conformations.
6.7. Bacteriology
Susceptibility testing was performed and interpreted following
the guidelines of the National Committee for Clinical Laboratory
Standards [46], with the exception of experiments performed
with a laboratory strain of JM109 E. coli. To test the inhibitory
activity of 2 and 33, the compounds were dissolved in 50%
DMSO, and dilutions were performed using growth medium.
An adequate ¢nal concentration in which to determine the
MIC was obtained where the concentration of DMSO was main-
tained below 5%. The MIC of amoxicillin, in the presence and
absence of the boronic acids, was determined against several
Gram-positive resistant clinical isolates from the Hospital Ramo¤n
y Cajal, Madrid, that show a group II L-lactamase phenotype
(Table 4).
For susceptibility testing against a laboratory strain of JM109
E. coli expressing AmpC, 33 was dissolved in DMSO at a con-
centration of 10 mM and diluted into LB broth to 400 WM (6 2%
DMSO). Compound 33 had no e¡ect on its own at this concen-
tration. This solution was serially diluted into 1 ml volumes of
LB that also contained 200 Wg/ml ampicillin. Each tube was then
inoculated with 10 Wl of a fresh overnight culture of JM109 E.
coli expressing AmpC on a temperature-inducible plasmid. The
cultures were incubated at 37‡C overnight with shaking. The
concentration of 33, in combination with ampicillin, at which
no growth was observed was determined visually.
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